Chad Beyer

Chad E. Beyer, Ph.D., MBA, is the Chief Executive Officer of Kures Therapeutics, Inc., a position he assumed on July 1, 2022.1 He has over 25 years of experience in the discovery, research, and translational development of medications for central nervous system and neurological disorders.1

Prior to joining Kures, Dr. Beyer served as the Senior Vice President of Research and Development at Promentis Pharmaceuticals, Inc.12 Throughout his career, he has led several preclinical and clinical drug discovery teams, participated in the submission of more than 30 INDs, and provided supporting data for the commercialization and life-cycle management of two blockbuster medications.1

Dr. Beyer is also an accomplished author, having written more than 70 manuscripts and co-edited the book "Next Generation Antidepressants".1 He co-founded the journal "Technology Transfer & Entrepreneurship".1

At Kures, Dr. Beyer is involved in developing KUR-101, a treatment for opioid use disorder (OUD).13 He has expressed urgency in continuing the development of KUR-101, noting the critical need for addressing the opioid crisis.3

Dr. Beyer holds a Ph.D. and an MBA.4 His expertise includes areas such as chromatography, clinical trials, and medical writing.4